Year: 2020
Type: review
Abstract: Multiple myeloma (MM) is the second most common hematologic malignancy in the world. Even though survival rates have significantly risen over the past years, MM remains incurable, and is also far from reaching the point of being managed as a chronic disease. This paper reviews the evolution of MM therapies, focusing on anti-MM drugs that target the molecular mechanisms of nuclear factor kappa B (NF-κB) signaling. We also provide our perspectives on contemporary research findings and insights for future drug development.
Source: Cancers
Institutions: Agency for Science, Technology and Research, Institute of Molecular and Cell Biology, South Australia Pathology, National University of Singapore, University of South Australia, Centre for Cancer Biology, National University Cancer Institute, Singapore, National University Health System, Cancer Science Institute of Singapore
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,324
OpenAlex ID: W3047390373